Abstract

Re-irradiation with intensity-modulated radiotherapy (IMRT) remains the primary treatment modality for inoperable locally recurrent nasopharyngeal carcinoma (NPC). However, the rate of radiation-related late adverse effects is often substantially high. Therefore, we aimed to explore failure patterns and individualized treatment plans of re-irradiation for inoperable locally recurrent NPC. Ninety-seven patients who underwent IMRT were retrospectively analyzed. Sixty-two patients had clinical target volume of recurrence (rCTV) delineated, and thirty-five patients had only gross tumor volume of recurrence (rGTV) delineated. Twenty-nine patients developed second local failures after re-irradiation with IMRT (28 cases available). Among those patients, 64.3% (18/28) of patients and 35.7% (10/28) developed in-field or out-field, respectively. No statistical correlation was observed between target volume (rGTV or rCTV) and the local recurrence rate, local failure patterns, grade ≥ 3 toxicity, and survival. Multivariate analysis showed that recurrent T (rT) stage (HR 2.62, P = 0.019) and rGTV volume (HR 1.73, P = 0.037) were independent prognostic factors for overall survival (OS). Risk stratification based on rT stage and rGTV volume revealed that low risk group had a longer 3-year OS rate (66.7% vs. 23.4%), lower total grade ≥ 3 toxicity (P = 0.004), and lower re-radiation associated mortality rates (HR 0.45, P = 0.03) than high risk group. This study demonstrates that the delineation of rCTV may not be beneficial for re-irradiation using IMRT in locally recurrent NPC. Patients with low risk were most suitable for re-irradiation, with maximizing local salvage and minimizing radiation-related toxicities. More precise and individualized plans of re-irradiation are warranted.

Details

Title
Failure patterns and individualized treatment plans of reirradiation for inoperable locally recurrent nasopharyngeal carcinoma
Author
Lin, Cheng 1 ; Lu, Qiongjiao 2 ; Chen, Yuebing 1 ; Chen, Xiaoqiang 3 ; Huang, Yiping 1 ; Zhong, Hangyan 1 ; Peng, Xiane 4 ; Hu, Cairong 1 ; Chen, Bijuan 1 ; Lin, Shaojun 5 ; Zong, Jingfeng 1 

 Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Radiation Oncology, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307) 
 Zhangzhou Affiliated Hospital of Fujian Medical University, Department of Radiation Oncology, Zhangzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307) 
 Fujian Medical University Union Hospital, Department of Otolaryngology, Fuzhou, China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478) 
 Fujian Medical University, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307) 
 Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Radiation Oncology, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307); Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China (GRID:grid.256112.3) 
Pages
17887
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3087465458
Copyright
© The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.